Payden & Rygel Makes New $19.71 Million Investment in CVS Health Corporation $CVS

Payden & Rygel bought a new position in CVS Health Corporation (NYSE:CVS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 261,500 shares of the pharmacy operator’s stock, valued at approximately $19,714,000. CVS Health accounts for approximately 1.6% of Payden & Rygel’s holdings, making the stock its 19th biggest position.

Other large investors have also made changes to their positions in the company. SOA Wealth Advisors LLC. boosted its stake in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the period. Alteri Wealth LLC lifted its holdings in shares of CVS Health by 3.2% in the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock valued at $316,000 after purchasing an additional 131 shares in the last quarter. Holistic Financial Partners boosted its position in shares of CVS Health by 4.1% in the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock worth $256,000 after buying an additional 133 shares during the period. Symmetry Partners LLC grew its holdings in shares of CVS Health by 2.5% during the third quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after buying an additional 141 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its position in CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 142 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS opened at $76.64 on Monday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The firm has a market cap of $97.50 billion, a PE ratio of 55.53, a PEG ratio of 0.80 and a beta of 0.50. The firm’s 50 day moving average price is $78.52 and its 200 day moving average price is $76.87. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, research analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. CVS Health’s payout ratio is currently 192.75%.

Analyst Ratings Changes

A number of brokerages have commented on CVS. Wall Street Zen lowered CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Barclays boosted their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Raymond James Financial upped their price objective on shares of CVS Health from $75.00 to $90.00 in a research note on Friday, October 31st. Finally, Evercore lifted their target price on shares of CVS Health from $85.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Nineteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $94.91.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.